PT1126870E - Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose - Google Patents

Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose

Info

Publication number
PT1126870E
PT1126870E PT99956559T PT99956559T PT1126870E PT 1126870 E PT1126870 E PT 1126870E PT 99956559 T PT99956559 T PT 99956559T PT 99956559 T PT99956559 T PT 99956559T PT 1126870 E PT1126870 E PT 1126870E
Authority
PT
Portugal
Prior art keywords
vegf
restenosis
gene
protein
prevention
Prior art date
Application number
PT99956559T
Other languages
English (en)
Portuguese (pt)
Inventor
Yla-Herttuala Seppo
Alitalo Kari
Mikko O Hiltunen
Markku M Jeltsch
Marc G Achen
Original Assignee
Licentia Ltd
Ludwig Inst Cancer Res
Seppo Yla Herttuala
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd, Ludwig Inst Cancer Res, Seppo Yla Herttuala filed Critical Licentia Ltd
Publication of PT1126870E publication Critical patent/PT1126870E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99956559T 1998-10-26 1999-10-26 Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose PT1126870E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26

Publications (1)

Publication Number Publication Date
PT1126870E true PT1126870E (pt) 2005-01-31

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99956559T PT1126870E (pt) 1998-10-26 1999-10-26 Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose

Country Status (12)

Country Link
EP (1) EP1126870B1 (enExample)
JP (2) JP4769929B2 (enExample)
CN (1) CN1338943A (enExample)
AT (1) ATE275417T1 (enExample)
AU (1) AU768330B2 (enExample)
CA (1) CA2340593C (enExample)
DE (1) DE69920031T2 (enExample)
ES (1) ES2229788T3 (enExample)
NO (1) NO20012017L (enExample)
NZ (1) NZ510121A (enExample)
PT (1) PT1126870E (enExample)
WO (1) WO2000024412A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
JP4981229B2 (ja) 2000-02-25 2012-07-18 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ハイブリッド血管内皮成長因子ＤＮＡｓおよびタンパク質に関与する物質および方法
AU2001268149B2 (en) * 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
DK2314293T3 (en) 2001-01-16 2017-04-18 Vascular Therapies Llc IMPLANTABLE DEVICE CONTAINING RESORBABLE MATERIAL MATERIAL AND RAPAMYCINE FOR PREVENTION OR TREATMENT OF VASCULOPROLIFERATIVE DISEASES
MXPA03009408A (es) 2001-04-13 2004-01-29 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
BR0309676A (pt) * 2002-04-30 2005-02-22 Fit Biotech Oyl Plc Dispositivo médico
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
US20070254956A1 (en) * 2003-10-29 2007-11-01 Koichi Shudo Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation
JP4832290B2 (ja) * 2004-03-18 2011-12-07 健輔 江頭 薬剤・遺伝子溶出型ステント
EP1919944B1 (en) 2005-08-15 2011-03-23 Vegenics Pty Ltd Modified vegf and pdgf with improved angiogenic properties
CA2663547C (en) 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
JP2011512408A (ja) 2008-02-19 2011-04-21 セラドン・コーポレーション 心筋層へのウイルスベクターの取り込みを増大させるための組成物
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
CA3131428A1 (en) * 2019-03-29 2020-10-08 Jerald Wayne CURRAN Systems and methods for left ventricular unloading in biologic therapy or vectored gene therapy
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
DE69734359T2 (de) * 1996-08-23 2006-07-06 Ludwig Institute For Cancer Research Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
WO1998049300A2 (en) * 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins

Also Published As

Publication number Publication date
JP5231587B2 (ja) 2013-07-10
CA2340593C (en) 2012-05-08
WO2000024412A3 (en) 2000-08-03
EP1126870A2 (en) 2001-08-29
CN1338943A (zh) 2002-03-06
NO20012017D0 (no) 2001-04-24
NO20012017L (no) 2001-06-26
DE69920031D1 (de) 2004-10-14
AU768330B2 (en) 2003-12-11
DE69920031T2 (de) 2005-09-22
NZ510121A (en) 2003-02-28
WO2000024412A2 (en) 2000-05-04
EP1126870B1 (en) 2004-09-08
ATE275417T1 (de) 2004-09-15
JP2002528420A (ja) 2002-09-03
AU1314700A (en) 2000-05-15
JP4769929B2 (ja) 2011-09-07
CA2340593A1 (en) 2000-05-04
ES2229788T3 (es) 2005-04-16
JP2011173874A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
PT1126870E (pt) Utilizacao do gene vegf-c ou vegf-d ou de uma proteina na prevencao da restenose
DE69936312D1 (de) Mutanten von op-1
DK0690872T3 (da) Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
DE69113470D1 (de) Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln.
JP2002531055A5 (enExample)
ATE163046T1 (de) Genetische veränderung von endothelzellen
PT814827E (pt) Factor de crescimento vascular endotelial-b
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
SE8902532L (sv) Bestaemning av plasmaproteiner
ATE438361T1 (de) Stent beschichtet mit dna
WO2003010201A3 (en) Blood group antigen fusion polypeptides and methods of use thereof
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
WO2003039491A8 (en) Novel isoforms of vascular endothelial cell growth inhibitor
DK1169058T3 (da) Insulinlignende vækstfaktorbindingsprotein-4-protease
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
DE69636367D1 (de) T-pa polymorphismus und dessen verwendung zur risikodiagnose von thrombus assoziierten krankheiten
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
AU4662400A (en) Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff